CG Invites reports successful induction of strong immunogenicity from joint research with HLB group on personalized 안전한 바카라사이트 산타카지노 vaccine

[by Yu, Suin] CG Invites announced on May 22 that a personalized cancer vaccine study, conducted in collaboration with global 안전한 바카라사이트 산타카지노 drug developer HLB and its U.S. subsidiary Immunomic Therapeutics (ITI), demonstrated that an 안전한 바카라사이트 산타카지노 vaccine candidate, developed using an AI-based neoantigen prediction algorithm and a self-replicating mRNA platform, successfully induced strong immunogenicity in an animal model.

A personalized cancer vaccine represents a form of true ‘personalized treatment,’ designed to stimulate the patient’s immune system to target cancer cells by utilizing specific mutations unique to those cells. This approach is regarded as one of the most promising future 안전한 바카라사이트 산타카지노 therapies, as it leverages the patient’s own cancer mutation profile and immune system to minimize side effects, maximize therapeutic efficacy, and reduce the risk of cancer recurrence.

This joint research was carried out using CG Invites’ AI-based neoantigen prediction algorithm, imNEO, to identify tumor-specific neoantigens from a colorectal 안전한 바카라사이트 산타카지노 mouse model. These neoantigens were then incorporated into ITI’s self-amplifying mRNA (saRNA) platform to assess the resulting immune response. The study was conducted in collaboration between the two companies under HLB’s open innovation strategy.

The objective of this study was to determine whether the high immunogenicity (2.8 times more accurate than that of the global leading group) and the 안전한 바카라사이트 산타카지노 effects (tumor growth inhibition and antibody production), previously validated by CG Invites through peptide-based 안전한 바카라사이트 산타카지노 vaccine animal studies, could be replicated using an mRNA platform. The results confirmed that the group of mice administered the 안전한 바카라사이트 산타카지노 vaccine exhibited a strong immune response. Notably, even a small dose of 1μg (microgram), highlighting a key advantage of the self-replicating mRNA approach, showed sufficient effects, demonstrating exceptional platform efficiency.

The successful application of the mRNA platform is anticipated to offer substantial advantages not only in enhancing the efficacy of 안전한 바카라사이트 산타카지노 vaccines, but also in improving production speed and cost efficiency. The company expects that these benefits will dramatically increase the clinical feasibility of the vaccine.

“Achieving both speed and precision in the mRNA platform is a crucial element in the development of personalized 안전한 바카라사이트 산타카지노 vaccines, and this outcome marks a significant milestone, demonstrating that the AI ​​prediction technology validated in peptide-based approaches can also be successfully applied to the mRNA platform,” expressed Cho Yun-sung, CTO of Invites Ecosystem. “We anticipate that AI × mRNA-based platform technology will play a vital role in the development of a wide range of future biopharmaceuticals.”

“This joint research is being promoted as part of HLB’s open innovation strategy. Moving forward, we plan to integrate the vaccine platform, drug delivery systems, immunogenicity and 안전한 바카라사이트 산타카지노 efficacy evaluation technologies, as well as GLP toxicity assessment capabilities held by HLB Group companies, to collaboratively develop a next-generation personalized 안전한 바카라사이트 산타카지노 vaccine with CG Invites that will lead the global market,” said Han Yong-hae, CTO of HLB Group.

Building on the successful outcomes of this joint research, CG Invites, HLB, and ITI plan to maintain close collaboration with the shared goal of leading the paradigm shift toward next-generation personalized 안전한 바카라사이트 산타카지노 treatment with strong global competitiveness.